Description of Whitehawk Therapeutics Inc's Business Segments

The Company operates a single reportable segment focused on applying advanced technologies to established tumor biology to develop cancer treatments. The Chief Executive Officer serves as the chief operating decision maker, evaluating performance based on research and development expenses and net income or loss. Segment revenues were derived from sales of FYARRO, which was divested on March 25, 2025. All segment assets and operations are based in the United States. Major segment expenses include research and development, contract manufacturing, commercial and marketing, finance and accounting, legal, selling, general and administrative expenses, cost of sales, interest expense, other income, foreign exchange loss, and gain on sale of business. The Company divested FYARRO by selling 100% of the outstanding shares of Aadi Subsidiary to KAKEN PHARMACEUTICAL CO., LTD, receiving $102.4 million in cash and recording a net gain of $87.3 million on the sale at closing on March 25, 2025.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Annual Report on Whitehawk Therapeutics Inc Divisions, Sales by Country


Reportable Segment		100 %	of total Revenue

Twelve months ended 2025
WHWK s Annual Revenue by Geography and Business Segments	Sales (in millions $)	% (of total Sales)
Total	7.15	100 %
Reportable Segment	7.15	100 %

Twelve months ended 2025
WHWK s Annual Income by Country and Business Segments	Income (in millions $)	% (Profit Margin)
Total	-20.60	-
Reportable Segment	-20.60	-

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments	% Y/Y Sales Growth	% Y/Y Income Growth
Total	-72.5 %	-
Reportable Segment	-72.5 %	-

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.